Developing new drugs for cancers driven by RAS-MAPK pathways
Molecular Glues to Target RAS-MAPK Driven Cancers
This study is working on new types of cancer drugs that aim to be safer and more effective by targeting specific parts of a key pathway involved in cancer growth, which could help patients with different cancers, including colorectal cancer, and reduce side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11015050 on NIH RePORTER |
What this research studies
This research focuses on creating a new class of drugs that target specific binding sites in the RAS-MAPK signaling pathway, which is crucial in many cancers. By avoiding traditional drug design that targets active sites, the approach aims to enhance drug selectivity and reduce side effects, potentially overcoming issues like drug resistance. The research involves detailed structural studies of key proteins involved in cancer, which will guide the development of safer and more effective therapies for patients. This innovative strategy could lead to breakthroughs in treating various cancers, including colorectal cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with RAS-MAPK driven cancers, such as those with mutations in KRAS or BRAF.
Not a fit: Patients with cancers not driven by RAS-MAPK pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments with fewer side effects for patients.
How similar studies have performed: Other research has shown promise in targeting similar pathways, but this approach is innovative and aims to address limitations of existing therapies.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Dar, Arvin — Sloan-Kettering Inst Can Research
- Study coordinator: Dar, Arvin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.